# Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/trastuzumab-emtansine-delays-and-overcomes-resistance-to-the-third-generation/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Silvia La Monica,Daniele Cretella,Mara Bonelli,Claudia Fumarola,Andrea Cavazzoni,Graziana Digiacomo,Lisa Flammini,Elisabetta Barocelli,Roberta Minari,Nadia Naldi,Pier Giorgio Petronini,Marcello Tiseo,Roberta Alfieri |
| Citations | 89 |
| DOI | 10.1186/s13046-017-0653-7 |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://jeccr.biomedcentral.com/counter/pdf/10.1186/s13046-017-0653-7 |
| OpenAlex ID | https://openalex.org/W2772606138 |
| PMID | 29202823 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Silvia La Monica](https://scholariq.org/researchers/silvia-la-monica/)

## Paper journal

- [Journal of Experimental & Clinical Cancer Research](https://scholariq.org/journals/journal-of-experimental-and-clinical-cancer-research/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.